MedPath

Resonance Health Ltd

Ownership
-
Employees
18
Market Cap
-
Website
Introduction

Resonance Health Ltd is a healthcare company specializing in the development and commercialization of technologies and services for the quantitative analysis of radiological images in a regulated and quality-controlled environment. Its product includes FerriScan, a non-invasive liver diagnostic technology used for the measurement of iron in the liver, Cardiac T2, and HepaFat-Scan. It also has several AI-assisted SaMDs including FerriSmart, HepaFat-AI, and LiverSmart. The company's business segments are; Services which derives key revenue, Research and development, Corporate, Clinical Research Organization (CRO), and TrialsWest. Geographically, it generates maximum revenue from the Asia Pacific and the rest from North America, and Europe, Middle East and Africa (EMEA) regions.

Resonance Health Secures $13.775 Million Clinical Trial Contract with Sun Pharma

• Resonance Health has been contracted by Sun Pharmaceutical Industries for a clinical trial in Australia, valued at AUD $13.775 million. • Resonance will provide CRO services, trial site services, and imaging analysis for Sun Pharma's new drug compound. • Patient recruitment is expected to commence in early 2025, pending regulatory approvals, with Resonance's TrialsWest sites playing a key role. • This agreement highlights Resonance's strategy to expand its presence in the global pharma and clinical trials market.
© Copyright 2025. All Rights Reserved by MedPath